Business Wire

Fusion Risk Management Announces Strategic Growth Investment from Great Hill Partners

Share

Fusion Risk Management, Inc. (“Fusion” or the “Company”), a leading provider of cloud-based operational resilience, business continuity, and risk management software and services, today announced a strategic growth investment from Great Hill Partners, a leading growth-oriented private equity firm. The majority investment will allow Fusion to enhance its go-to-market and product innovation capabilities, while continuing to accelerate the pursuit of several attractive organic and inorganic growth opportunities. Existing investor Vista Equity Partners (“Vista”) will remain a significant minority shareholder in Fusion, along with Catalyst Investors and Level Equity Management. Financial terms of the transaction were not disclosed.

Fusion has grown rapidly in recent years as organizations in regulated and non-regulated end markets shift from reactive approaches to proactive, real-time frameworks that unite risk across employees, third parties, processes, and technologies. The Company’s leading platform empowers its diverse base of 400+ blue chip customers with the knowledge and workflows they need to better mitigate threats, minimize downtime, maintain operational resilience, and sustain critical operations in the face of unexpected crises such as pandemics, geopolitical events, natural disasters, cyber-attacks, and more.

“As the risk landscape continues to evolve, now more than ever businesses need an agile and flexible operational resilience framework to navigate disruption and drive sustainable growth," said Michael Campbell, CEO of Fusion Risk Management. “Today’s milestone is a testament to Fusion’s capabilities in delivering data-driven, actionable insights that enable customers to develop dynamic plans and proactively address the risks and disruptions that have become ‘business as usual.’ We’re confident that Great Hill will be an invaluable partner as we leverage their deep industry expertise and resources to further unlock the potential of our platform and accelerate our mission to make true business resiliency a reality.”

“Fusion is a clear leader in the risk management space, driving unparalleled value for its customers by providing them with the comprehensive tools they need to become more aware, prepared, and resilient,” said Chris Busby, Managing Director at Great Hill. “The Company fits the exact profile of the type of business we aim to invest in: high-growth companies that are driving transformative change in their industries. Leveraging our significant software and growth-investment experience, Fusion has tremendous potential to capitalize on opportunities ahead amid significant compliance and regulatory tailwinds and to continue deepening its strong, longstanding customer relationships. We’re excited to partner with Michael, the entire management team, and Vista to strengthen Fusion’s position at the forefront of operational resilience and risk management software.”

“Since our partnership began, Fusion and Vista have been focused on transforming the Company into a leading platform through product innovation and scaling its go-to-market capabilities to meet customers’ growing demand to build resilient organizations,” said René Yang Stewart, Co-Head of Vista’s Endeavor Fund and Senior Managing Director. “We are thrilled to continue this momentum by welcoming Great Hill Partners and embarking on the next chapter of Fusion’s growth trajectory.”

In addition to Fusion Risk Management, Great Hill Partners' portfolio of enterprise software companies includes eloomi, BigChange, Auvik, Varicent, Totango, and Intapp, among several others. Prior software investments include Reflexis Systems, Reward Gateway, PlanSource, ZoomInfo, and more.

William Blair & Company served as exclusive financial advisor to Fusion Risk Management. Kirkland & Ellis LLP served as legal advisor to Great Hill Partners and to Fusion.

About Fusion Risk Management, Inc.

Fusion Risk Management is a leading industry provider of cloud-based operational resilience software, encompassing business continuity and disaster recovery, risk management, information technology and security risk management, crisis and incident management, and more. Its solutions empower organizations to make data-driven decisions with a holistic, agile approach and enable them to deliver on their brand promise through disruption. For more information, visit www.fusionrm.com.

About Great Hill Partners

Founded in 1998, Great Hill Partners is a private equity firm targeting investments of $100 million to $500 million in high-growth companies across the software, digital commerce, financial technology, healthcare, and digital infrastructure sectors. With offices in Boston and London, Great Hill has raised over $12 billion of commitments and invested in more than 95 companies, establishing an extensive track record of building long-term partnerships with entrepreneurs and providing flexible resources to help middle-market companies scale. Great Hill has been recognized for its industry leadership, being ranked #3 in the 2022 HEC Paris-Dow Jones Mid-Market Buyout Performance Ranking, which evaluated fund performance of 563 leading private equity firms between 2009-2018. For more information, including a list of all Great Hill investments, visit www.greathillpartners.com.

About Vista Equity Partners

Vista is a leading global investment firm with more than $96 billion in assets under management as of December 31, 2022. The firm exclusively invests in enterprise software, data and technology-enabled organizations across private equity, permanent capital, credit and public equity strategies, bringing an approach that prioritizes creating enduring market value for the benefit of its global ecosystem of investors, companies, customers and employees. Vista's investments are anchored by a sizable long-term capital base, experience in structuring technology-oriented transactions and proven, flexible management techniques that drive sustainable growth. Vista believes the transformative power of technology is the key to an even better future – a healthier planet, a smarter economy, a diverse and inclusive community and a broader path to prosperity. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on Twitter, @Vista_Equity.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fusion:
Terese Fernandez
Fusion Risk Management
917.640.1016

For Great Hill Partners:
Danya Al-Qattan / Zachary Tramonti / Kevin Siegel
greathill@fgsglobal.com
(212) 687-8080

For Vista Equity Partners:
Brian W. Steel
media@vistaequitypartners.com
(212) 804-9170

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye